Cameron McDaniel, a 2018 graduate of the doctoral program in the UC Department of Molecular Genetics, Biochemistry and Microbiology, is the paper’s first author. McDaniel is also a former postdoctoral candidate in the UC College of Pharmacy.
Hassett said a core group of researchers at UC also worked with colleagues at Cincinnati Children’s Hospital Medical Center and scientists from Canada and other universities across the United States. Other study co-authors in the UC Department of Molecular Genetics, Biochemistry and Microbiology are Warunya Panmanee, Andrew Paul, Seung-Hyun Ko, Amy Bogue and William Miller.
Co-authors and researchers from Cincinnati Children’s Hospital are Nupur Dasgupta, Joel Mortensen, Phillip Dexheimer, David Haslam and Bruce Aronow. Co-authors from Simon Fraser University in Burnaby, Canada, are Geoffrey Winsor, Claire Bertelli and Fiona Brinksman. Other co-authors include Erin Gill and Robert Hancock, both of the University of British Columbia, Vancouver, Canada; Daniel Muruve, University of Calgary; Michael Schurr of the University of Colorado, Denver; Prateek Donagare and Thomas Meyer, both of the University of North Carolina at Chapel Hill; Gee Lau of the University of Illinois at Urbana-Champaign; and Marek Danilczuk and Malcolm D.E. Forbes, both of Bowling Green State University.
Disclosures: Hassett is a stockholder and principal scientist at Arch Biopartners. AB569 is currently in a Phase 1 human trial at the Cincinnati VA Medical Center in healthy volunteers testing its safety and pharmacokinetic profile. Muruve is a co-founder and chief security officer for Arch Biopartners. AB569 has been licensed by the University of Cincinnati exclusively to Arch Biopartners, a Toronto-based publicly traded biotechnology company.
Featured photo at top: Daniel Hassett, PhD/Colleen Kelley/UC Creative Services.